Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
8.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

495
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
495
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

749
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
749

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The hospital frailty risk score in patients with heart failure is strongly associated with outcomes but less so with pharmacotherapy.

Journal of internal medicine·2019
Same author

Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease.

Journal of internal medicine·2017
Same author

Effect of nesiritide in patients with acute decompensated heart failure.

The New England journal of medicine·2011
Same author

Benefit of angiographic spontaneous reperfusion in STEMI: does it extend to diabetic patients?

Heart (British Cardiac Society)·2009
Same author

Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation.

Heart (British Cardiac Society)·2008
Same author

It's a matter of time: contemporary pre-hospital management of acute ST elevation myocardial infarction.

Heart (British Cardiac Society)·2005
Same journal

Disrupted erythrocyte S1P-eNOS axis promotes hypoxia, hypertension and fibrosis in obstructive sleep apnoea-hypopnoea syndrome.

European heart journal·2026
Same journal

Stroke and systemic embolism following AF ablation: importance of global registries.

European heart journal·2026
Same journal

Update on lipoprotein(a): the rising star in residual lipid risk.

European heart journal·2026
Same journal

Great debate: medical treatment of heart failure with reduced ejection fraction will rely on four foundational drugs.

European heart journal·2026
Same journal

The surgical collateralization theory: has the beautiful hypothesis been killed by the ugly facts?

European heart journal·2026
Same journal

Beyond single measurement: additional considerations for high-sensitivity C-reactive protein in cardiovascular risk prediction.

European heart journal·2026
See all related articles

Related Experiment Video

Updated: May 5, 2026

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 27, 2013

25.1K

Perspectives gained from large-scale thrombolytic comparative trials.

P W Armstrong1

  • 1Division of Cardiology, Department of Medicine, 2F1.30 WMC, University of Alberta, Edmonton, Alberta, Canada T6G 2R7.

European Heart Journal
|September 1, 1996
PubMed
Summary
This summary is machine-generated.

Accelerated tissue plasminogen activator (t-PA) with heparin improves outcomes in acute myocardial infarction. Identifying patient subsets and bleeding risks optimizes treatment decisions for better survival and cardiac function.

More Related Videos

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

14.4K
The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo
06:38

The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo

Published on: December 19, 2025

495

Related Experiment Videos

Last Updated: May 5, 2026

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 27, 2013

25.1K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

14.4K
The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo
06:38

The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo

Published on: December 19, 2025

495

Area of Science:

  • Cardiology
  • Clinical Trials
  • Pharmacology

Background:

  • Four large thrombolytic trials (GISSI-2, ISIS-3, GUSTO, INJECT) compared treatments for acute myocardial infarction (AMI).
  • Differences in GUSTO results were linked to intravenous heparin and accelerated tissue plasminogen activator (t-PA) regimens.

Purpose of the Study:

  • To identify patient subsets benefiting most from accelerated t-PA.
  • To develop a profile for patients at risk of intracranial hemorrhage.
  • To assess the impact of early coronary artery patency on left ventricular function and survival.

Main Methods:

  • Analysis of predefined parameters in large patient populations (>1000).
  • Angiographic substudy within the GUSTO trial.
  • Evaluation of international practice patterns, quality of life, and return to work.

Main Results:

  • Accelerated t-PA with heparin demonstrated improved outcomes compared to earlier strategies.
  • Patient-specific risk profiles for intracranial hemorrhage were identified.
  • Early coronary artery patency significantly improved left ventricular function and survival.

Conclusions:

  • Individualized treatment decisions using patient profiles enhance care for AMI.
  • Left ventricular function serves as a valuable surrogate for assessing reperfusion strategies.
  • Future research should focus on resource optimization for novel therapy assessment in AMI.